QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: GVP Module VII Benefit-Risk Evaluation in the PSUR

Test your understanding of the concepts covered by GVP Module VII: Benefit-Risk Evaluation in the PSUR.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best distinguishes statistical significance from clinical importance in benefit evaluation?

A statistically significant finding is always clinically important A clinically important benefit must always be statistically significant Statistical precision and clinical relevance are separate considerations that should both be assessed Clinical importance is determined solely by sample size

Question 2 of 10 A medicine is authorised for two indications. The benefit is substantial in one indication but modest in the other, while the principal serious risk is similar. What is the most appropriate PSUR approach?

Present one product-level conclusion because the risk is shared Evaluate and present the benefit-risk balance separately by indication Exclude the risk from the indication with the greater benefit Use the indication with the largest patient population as the basis for the overall conclusion

Question 3 of 10 Which statement best captures the relationship between evidence and the final PSUR conclusion?

The conclusion may introduce major assertions not addressed in the assessment if they are clinically plausible The conclusion should follow visibly from the evidence, interpretation, context and uncertainty discussed earlier The conclusion should focus only on whether the number of reports increased The conclusion is independent of proposed regulatory or risk-management actions

Question 4 of 10 What is the primary purpose of the integrated benefit-risk evaluation in a PSUR?

To reproduce the detailed safety listings presented in earlier PSUR sections To integrate key benefits, risks, clinical context and uncertainty into a regulatory conclusion To calculate a universal numerical ratio between efficacy and adverse-event frequency To summarise only newly identified safety signals from the reporting interval

Question 5 of 10 What is the principal value of distinguishing a population-specific difference from an apparent difference caused by exposure or reporting patterns?

It prevents any subgroup analysis from being performed It helps ensure that regulatory conclusions and risk minimisation target a genuine clinical difference rather than an artefact It allows the overall product-level conclusion to replace all subgroup evaluation It establishes causality whenever reporting differs between populations

Question 6 of 10 Which finding would most clearly justify reassessment of an existing favourable benefit-risk conclusion?

A minor increase in reports with no change in exposure, seriousness or clinical pattern Evidence that an important risk affects a broader population and is less preventable than previously understood A formatting change in the product information The absence of a new validated signal despite continued monitoring

Question 7 of 10 Which activity best demonstrates substantive QPPV oversight of a PSUR benefit-risk conclusion?

Signing the final document without reviewing the underlying rationale Personally reproducing every statistical analysis in the PSUR Challenging whether major safety issues, uncertainties, indication differences, RMP implications and proposed actions are adequately addressed Delegating all benefit-risk questions to the product-information function

Question 8 of 10 Which statement best describes the relationship between a PSUR and an RMP?

The PSUR and RMP are interchangeable documents with the same purpose The PSUR evaluates accumulated evidence and its implications, while the RMP describes how risks and missing information are managed The RMP determines the benefit-risk conclusion and the PSUR records it without reassessment The PSUR addresses only efficacy and the RMP addresses only adverse-event counts

Question 9 of 10 A PSUR discusses a major new safety concern but contains no assessment of whether the RMP should change. What does this suggest?

This is appropriate because PSURs and RMPs must never interact It may represent a governance weakness because material safety findings should be assessed for RMP implications The RMP can only be changed after a marketing authorisation withdrawal RMP implications are relevant only for efficacy findings

Question 10 of 10 Which economic consideration is outside the defined GVP Module VII benefit-risk evaluation?

The clinical seriousness of the treated disease The availability of therapeutically meaningful alternatives The cost-effectiveness of the medicinal product The consequences of untreated disease

QPPV.com

Knowledge Assessment: GVP Module VII Benefit-Risk Evaluation in the PSUR

Cookie Settings